SCHEDULE 13D/A

Keros Therapeutics Inc

Common Stock, Par Value $0.0001 Per Share · CUSIP: 492327101

Event date: 2025-04-17

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares

Unavailable

Percent of class

Unavailable

• Pontifax Management 4 GP (2015) Ltd.Reported CIK 0001726334

  Shares: 4,787,331.00 · Class: 11.8%

• Pontifax (Israel) IV, L.P.

  Shares: 2,284,612.00 · Class: 5.6%

• Pontifax (Cayman) IV, L.P.

  Shares: 1,121,045.00 · Class: 2.8%

• Pontifax (China) IV, L.P.

  Shares: 1,226,412.00 · Class: 3.0%

• Pontifax Late Stage Fund L.P.

  Shares: 155,262.00 · Class: 0.4%

• Pontifax Late Stage GP Ltd.

  Shares: 155,262.00 · Class: 0.4%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.